

## WHAT IS CLAIMED IS:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding mPGES-1, wherein said antisense compound specifically hybridizes with and inhibits the expression of mPGES-1.
2. The antisense compound of claim 1 wherein said antisense compound is an antisense oligonucleotide.
3. The antisense compound of claim 2 wherein said antisense oligonucleotide comprises at least 8 contiguous nucleic acids of a nucleic acid sequence of SEQ ID NO.1 – SEQ ID NO:1802.
4. The antisense compound of claim 3 wherein said antisense oligonucleotide comprises a nucleic acid sequence of SEQ ID NO.1 – SEQ ID NO:1802.
5. The antisense compound of claim 2 wherein said antisense oligonucleotide consists of at least 8 contiguous nucleic acids of a nucleic acid sequence of SEQ ID NO.1 – SEQ ID NO:1802.
6. The antisense compound of claim 2 wherein said antisense oligonucleotide consists of a nucleic acid sequence of SEQ ID NO.1 – SEQ ID NO:1802.
7. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
8. The antisense compound of claim 7 wherein the modified internucleoside linkage is a phosphorothioate linkage.
9. The antisense compound of claim 2 or 7 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
10. The antisense compound of claim 9 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
11. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
12. The antisense compound of claim 11 wherein the modified nucleobase is a 5-methylcytosine.
13. The antisense compound of claim 9 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

14. The antisense compound of claim 13 wherein the modified nucleobase is a 5-methylcytosine.
15. The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
- 5 16. A composition comprising the antisense compound of claim 2 and a pharmaceutically acceptable carrier or diluent.
17. The composition of claim 16 further comprising a colloidal dispersion system.
18. A method of inhibiting the expression of mPGES1 in cells or tissues  
10 comprising contacting said cells or tissues with the antisense compound of claim 2 so that expression of mPGES-1 is inhibited.
19. A method of treating a human having a disease or condition associated with mPGES-1 comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 2 so that  
15 expression of mPGES-1 is inhibited.
20. The method of claim 19 wherein the disease or condition is arthritis
21. The method of claim 19 wherein the disease or condition is inflammation
22. The method of claim 19 wherein the disease or condition is pain
- 20 23. The method of claim 19 wherein the disease or condition is fever
24. The method of claim 19 wherein the disease or condition is cancer
25. The method of claim 19 wherein the disease or condition is alzheimer's
26. The method of claim 19 wherein the disease or condition is opthamic conditions
- 25 27. The method of claim 19 wherein the disease or condition is diabetes.
28. The method of claim 19 wherein the disease or condition is an immunological disorder.
29. The method of claim 19 wherein the disease or condition is a cardiovascular disorder.
- 30 30. The method of claim 19 wherein the disease or condition is a neurologic disorder.
31. The method of claim 19 wherein the disease or condition is ischemia/reperfusion injury.